Immunome

Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile See more here

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform - Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 - Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs - Zentalis to receive up-front payment of $35 million in cash…

Immunome Appoints Phil Roberts as Chief Technical Officer See more here

Immunome Appoints Carol A. Schafer to Board of Directors See more here

Immunome to Acquire Antibody-Related Assets and Materials from Atreca See more here

Immunome Reports Third Quarter 2023 Financial Results - Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - Bob Lechleider, M.D., appointed as Chief Medical Officer -…

Immunome Appoints Jean-Jacques Bienaimé to Board of Directors - Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors See more here

Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer - Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies  See more here